Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090005 | 0.95 | PIK3CD (0.53) | PIK3CDKDM4ETDP1PARP15PARP10 | |
| SCHEMBL5917486 | 0.94 | KDM4E (0.52) | PIK3CDKDM4ETDP1PARP15PARP10 | |
| SCHEMBL3069941 | 0.90 | PIK3CD (0.47) | PIK3CDKDM4ETDP1PARP15PARP10 | |
| SCHEMBL6953743 | 0.77 | PIK3CD (0.40) | PIK3CDKDM4ETDP1PARP15PARP10 | |
| SCHEMBL438637 | 0.76 | AR (0.47) | PIK3CDKDM4ETDP1PARP15PARP10 | |
| SCHEMBL11262249 | 0.74 | PIK3CD (0.36) | PIK3CDKDM4ETDP1PARP15PARP10 | |
| SCHEMBL12513519 | 0.74 | PIK3CD (0.45) | PIK3CDKDM4EHSD17B10CA12CA9 | |
| SCHEMBL5179312 | 0.74 | PIK3CD (0.40) | PIK3CDKDM4ETDP1PARP15PARP10 | |
| SCHEMBL3683020 | 0.74 | KDM4E (0.45) | PIK3CDKDM4ETDP1PARP15PARP10 | |
| SCHEMBL3277310 | 0.73 | HSD17B10 (0.46) | PIK3CDKDM4ETDP1PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2889309-B1 | MULTIMER OF EXTRACELLULAR DOMAIN OF PD-1 OR PD-L1 | ONO PHARMACEUTICAL CO (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-9783578-B2 | Immunosuppression modulating compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-10-10 | — | — | US | disclosed |
| EP-2889309-A1 | Tetramer of extracellular domain of PD-L1 | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-01 | — | — | EP | disclosed |
| EP-2468765-B1 | Tetramer of extracellular domain of PD-L1 | ONO PHARMACEUTICAL CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| EP-2468765-A9 | Tetramer of extracellular domain of PD-L1 | ONO Pharmaceutical Co., Ltd. (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-8907053-B2 | Immunosuppression modulating compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-8574872-B2 | Multimer of extracellular domain of cell surface functional molecule | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-1997887-B1 | MULTIMER OF EXTRACELLULAR DOMAIN OF CELL SURFACE FUNCTIONAL MOLECULE | ONO PHARMACEUTICAL CO (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2585099-A2 | IMMUNOSUPPRESSION MODULATING COMPOUNDS | Aurigene Discovery Technologies Limited (IN) | 2013-05-01 | — | — | EP | disclosed |
| EP-2468765-A1 | Multimer of extracellular domain of cell surface functional molecule | ONO Pharmaceutical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20110318373-A1 | IMMUNOSUPPRESSION MODULATING COMPOUNDS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2011-12-29 | — | — | US | disclosed |
| WO-2011161699-A2 | IMMUNOSUPPRESSION MODULATING COMPOUNDS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2011-12-29 | — | — | WO | disclosed |
| US-20110052448-A1 | SPECIFIC COMPONENT MEASURING METHOD BY SPECTRAL MEASUREMENT | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-7795034-B2 | Specific component measuring method by spectral measurement | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20090305950-A1 | MULTIMER OF EXTRACELLULAR DOMAIN OF CELL SURFACE FUNCTIONAL MOLECULE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1997887-A1 | MULTIMER OF EXTRACELLULAR DOMAIN OF CELL SURFACE FUNCTIONAL MOLECULE | Kyoto University (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20060170914-A1 | Specific component measuring method by spectral measurement | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060073526-A1 | Antibodies, assay method by using them and judgment method for pancreas cancer | WAKO PURE CHEMICAL INDUSTRIES, LTD | 2006-04-06 | — | — | US | disclosed |
| EP-1643240-A1 | SPECIFIC COMPONENT MEASURING METHOD BY SPECTRAL MEASUREMENT | Wako Pure Chemical Industries, Ltd. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318373-A1 | IMMUNOSUPPRESSION MODULATING COMPOUNDS | CD274, PDCD1, PDCD1LG2 | PIK3CD 596/4885KDM4E 2955/4885TDP1 2920/4885 |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | CD274, PDCD1, PDCD1LG2 | PIK3CD 558/4885KDM4E 3035/4885TDP1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.